A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Raphael Pharmaceutical's Debt-to-EBITDA or its related term are showing as below:
RAPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.51 Med: -0.03 Max: -0.03
Current: -0.04
During the past 6 years, the highest Debt-to-EBITDA Ratio of Raphael Pharmaceutical was -0.03. The lowest was -0.51. And the median was -0.03.
RAPH's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.67
vs RAPH: -0.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Raphael Pharmaceutical Debt-to-EBITDA Related Terms
Raphael Pharmaceutical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Raphael Pharmaceutical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPH vs TXMD, AYTU, MRMD: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Raphael Pharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raphael Pharmaceutical Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Raphael Pharmaceutical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Raphael Pharmaceutical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Raphael Pharmaceutical (RAPH) has a Debt-to-EBITDA of -0.04 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Raphael Pharmaceutical.
Is Raphael Pharmaceutical's Debt-to-EBITDA too high?
Raphael Pharmaceutical's current Debt-to-EBITDA is -0.04. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Debt-to-EBITDA compare to TXMD and AYTU?
Raphael Pharmaceutical's Debt-to-EBITDA of -0.04 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Raphael Pharmaceutical. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raphael Pharmaceutical's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Debt-to-EBITDA of -0.04. The current Debt-to-EBITDA is -0.04. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Debt-to-EBITDA is -0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score
Get the complete analysis for RAPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPH has been successfully added to your 
